News

Recent news

View
Sort
November 8, 2018

Merus to Present at the Jefferies 2018 London Healthcare Conference

UTRECHT, The Netherlands, November 8, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ton Logtenberg,...

September 27, 2018

Merus to Present at the Cantor Fitzgerald Global Healthcare Conference

UTRECHT, The Netherlands, September 27, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Hui Liu,...

September 27, 2018

Merus Strengthens Team with Key Appointments

Hui Liu, Ph.D., EVP, Chief Business Officer, appointed Head of Merus U.S. Peter B. Silverman, J.D., appointed EVP, General Counsel Jillian Connell joins as VP,...

August 30, 2018

Merus to Participate in Citi’s 13th Annual Biotech Conference

UTRECHT, The Netherlands, August 30, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ton Logtenberg,...

August 22, 2018

Merus Announces Formation of a Scientific Advisory Board

– Key Oncology and Drug Development Professionals to Support Advancement of Merus’ Pipeline of Bispecific Antibodies – UTRECHT, The Netherlands, August 22, 2018 (GLOBE NEWSWIRE) — Merus...

August 10, 2018

Merus Announces Financial Results for the Second Quarter 2018 & Mid-year Operating Results

– MCLA-128 Phase 1/2 clinical data from the gastric cancer cohort will be presented at the European Society for Medical Oncology Congress in October 2018...

August 7, 2018

Merus to Present at the 2018 Wedbush PacGrow Healthcare Conference

UTRECHT, The Netherlands, August 7, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Hui Liu,...

July 26, 2018

Merus Announces Recent Corporate Developments and Financial Results for the First Quarter 2018

– Initiation of Phase 1, first-in-human clinical trial of MCLA-158 in patients with solid tumors – – MCLA-128’s unique mechanism of action published in the...

July 5, 2018

Merus Announces Annual Meeting of Shareholders

UTRECHT, The Netherlands, July 5, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that...

May 31, 2018

Merus to Present at the Jefferies 2018 Healthcare Conference

UTRECHT, The Netherlands, May 31, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that...

May 24, 2018

Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors

– IND Accepted in April by the U.S. FDA for MCLA-158 – UTRECHT, The Netherlands, May 24, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a...

May 15, 2018

MERUS ANNOUNCES UNIQUE MECHANISM OF ACTION OF MCLA-128 THAT POTENTLY BLOCKS HER3 SIGNALING PUBLISHED IN CANCER CELL

UTRECHT, The Netherlands, May 15, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced the unique mechanism of action...

April 26, 2018

Merus Announces Recent Corporate Developments and Financial Results for the Fourth Quarter and Full Year 2017

– Phase 2 combination trial in two metastatic breast cancer (MBC) populations initiated for Merus’ most advanced bispecific antibody candidate, MCLA-128 – – Strategic collaboration...

April 19, 2018

Merus to Report Full Year 2017 Financial Results and Corporate Developments on April 26, 2018

UTRECHT, The Netherlands, April 19, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that...

March 20, 2018

Merus and the Vall d’Hebron Institute of Oncology Announce Research Collaboration to Develop Innovative Bispecific Antibodies for Therapeutic Applications in the Treatment of Cancer

UTRECHT, The Netherlands, March 20, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), and the Vall...

March 14, 2018

Merus announces Ono Pharmaceuticals exercise of its option for new research and licence agreement to generate Bispecific antibody targeting autoimmune diseases

UTRECHT, The Netherlands, March 14, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ono Pharmaceutical Co., LTD. (Osaka,...

March 13, 2018

Merus’ Intellectual Property portfolio expands with two new patents

Merus’ First U.S. Patent Covering MCLA-117 and Merus’ Spleen to Screen® Technology for Efficient Generation of Biclonics® Candidates UTRECHT, The Netherlands, March 13, 2018 (GLOBE NEWSWIRE) — Merus...

February 14, 2018

Merus Announces $55.8 Million Private Placement Offering of Common Stock

UTRECHT, The Netherlands, Feb. 14, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that it has...

January 26, 2018

Merus Announces First Patient Dosed in a Phase 2 Clinical Trial of MCLA-128 in Two Metastatic Breast Cancer Patient Populations

UTRECHT, the Netherlands, Jan. 26, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the...

January 9, 2018

Merus and Simcere announce strategic collaboration

UTRECHT, Netherlands and NANJING, China, Jan. 08, 2018 (GLOBE NEWSWIRE) — Merus (Nasdaq:MRUS) and Simcere Pharmaceutical Group today announced that Merus has agreed to grant Simcere an exclusive license to develop and...

January 4, 2018

Merus provides clinical updates for MCLA-117 and MCLA-158 programs

UTRECHT, The Netherlands, Jan. 04, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced the submission of an...

January 2, 2018

Merus to present at the 36th annual J.P. Morgan Healthcare conference

UTRECHT, The Netherlands, Jan. 02, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., Chief...

December 27, 2017

Announcement: Regeneron’s petition denied

MERUS ANNOUNCES THE U.S. COURT OF APPEALS FOR THE FEDERAL CIRCUIT DENIES REGENERON’S PETITION TO REHEAR THE PANEL’S DECISION AFFIRMING MERUS’ INEQUITABLE CONDUCT CLAIM AGAINST...

November 30, 2017

Merus announces 3rd quarter 2017 financial results and clinical highlights

UTRECHT, The Netherlands, Nov. 30, 2017 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced financial results for the...

November 9, 2017

Merus to present at the Jefferies London Healthcare Conference

UTRECHT, The Netherlands, Nov. 09, 2017 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, CEO, will present...

October 10, 2017

Merus to participate in the bio investor forum

UTRECHT, The Netherlands, Oct. 10, 2017 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, Ph.D., Chief Executive...

September 20, 2017

Merus’ intellectual property portfolio expands with two new patents for its biclonics® technology

UTRECHT, The Netherlands, Sept. 20, 2017 (GLOBE NEWSWIRE) — Merus (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing therapeutics with the goal of treating and curing serious illnesses, announced...

Highlighted news
November 8, 2018

Merus to Present at the Jefferies 2018 London Healthcare Conference

UTRECHT, The Netherlands, November 8, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ton Logtenberg,...

Read more
September 27, 2018

Merus to Present at the Cantor Fitzgerald Global Healthcare Conference

UTRECHT, The Netherlands, September 27, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Hui Liu,...

Read more
September 27, 2018

Merus Strengthens Team with Key Appointments

Hui Liu, Ph.D., EVP, Chief Business Officer, appointed Head of Merus U.S. Peter B. Silverman, J.D., appointed EVP, General Counsel Jillian Connell joins as VP,...

Read more
August 30, 2018

Merus to Participate in Citi’s 13th Annual Biotech Conference

UTRECHT, The Netherlands, August 30, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ton Logtenberg,...

Read more
August 22, 2018

Merus Announces Formation of a Scientific Advisory Board

– Key Oncology and Drug Development Professionals to Support Advancement of Merus’ Pipeline of Bispecific Antibodies – UTRECHT, The Netherlands, August 22, 2018 (GLOBE NEWSWIRE) — Merus...

Read more
August 10, 2018

Merus Announces Financial Results for the Second Quarter 2018 & Mid-year Operating Results

– MCLA-128 Phase 1/2 clinical data from the gastric cancer cohort will be presented at the European Society for Medical Oncology Congress in October 2018...

Read more
August 7, 2018

Merus to Present at the 2018 Wedbush PacGrow Healthcare Conference

UTRECHT, The Netherlands, August 7, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Hui Liu,...

Read more
July 26, 2018

Merus Announces Recent Corporate Developments and Financial Results for the First Quarter 2018

– Initiation of Phase 1, first-in-human clinical trial of MCLA-158 in patients with solid tumors – – MCLA-128’s unique mechanism of action published in the...

Read more
May 24, 2018

Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors

– IND Accepted in April by the U.S. FDA for MCLA-158 – UTRECHT, The Netherlands, May 24, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a...

Read more
May 15, 2018

MERUS ANNOUNCES UNIQUE MECHANISM OF ACTION OF MCLA-128 THAT POTENTLY BLOCKS HER3 SIGNALING PUBLISHED IN CANCER CELL

UTRECHT, The Netherlands, May 15, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced the unique mechanism of action...

Read more
March 20, 2018

Merus and the Vall d’Hebron Institute of Oncology Announce Research Collaboration to Develop Innovative Bispecific Antibodies for Therapeutic Applications in the Treatment of Cancer

UTRECHT, The Netherlands, March 20, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), and the Vall...

Read more
March 14, 2018

Merus announces Ono Pharmaceuticals exercise of its option for new research and licence agreement to generate Bispecific antibody targeting autoimmune diseases

UTRECHT, The Netherlands, March 14, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ono Pharmaceutical Co., LTD. (Osaka,...

Read more
March 13, 2018

Merus’ Intellectual Property portfolio expands with two new patents

Merus’ First U.S. Patent Covering MCLA-117 and Merus’ Spleen to Screen® Technology for Efficient Generation of Biclonics® Candidates UTRECHT, The Netherlands, March 13, 2018 (GLOBE NEWSWIRE) — Merus...

Read more
February 14, 2018

Merus Announces $55.8 Million Private Placement Offering of Common Stock

UTRECHT, The Netherlands, Feb. 14, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that it has...

Read more
January 26, 2018

Merus Announces First Patient Dosed in a Phase 2 Clinical Trial of MCLA-128 in Two Metastatic Breast Cancer Patient Populations

UTRECHT, the Netherlands, Jan. 26, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the...

Read more
January 9, 2018

Merus and Simcere announce strategic collaboration

UTRECHT, Netherlands and NANJING, China, Jan. 08, 2018 (GLOBE NEWSWIRE) — Merus (Nasdaq:MRUS) and Simcere Pharmaceutical Group today announced that Merus has agreed to grant Simcere an exclusive license to develop and...

Read more
January 4, 2018

Merus provides clinical updates for MCLA-117 and MCLA-158 programs

UTRECHT, The Netherlands, Jan. 04, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced the submission of an...

Read more
November 9, 2017

Merus to present at the Jefferies London Healthcare Conference

UTRECHT, The Netherlands, Nov. 09, 2017 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, CEO, will present...

Read more
September 20, 2017

Merus’ intellectual property portfolio expands with two new patents for its biclonics® technology

UTRECHT, The Netherlands, Sept. 20, 2017 (GLOBE NEWSWIRE) — Merus (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing therapeutics with the goal of treating and curing serious illnesses, announced...

Read more